MARC보기
LDR02178nam u200421 4500
001000000418850
00520190215163213
008181129s2016 |||||||||||||||||c||eng d
020 ▼a 9780438092679
035 ▼a (MiAaPQ)AAI10871471
035 ▼a (MiAaPQ)OhioLINK:osu1461200133
040 ▼a MiAaPQ ▼c MiAaPQ ▼d 247004
0820 ▼a 576
1001 ▼a Natarajan, Gayathri.
24514 ▼a The Use of a TEC Kinase Inhibitor, Ibrutinib, for the Development of Immunotherapies Against Cancer and Leishmaniasis.
260 ▼a [S.l.]: ▼b The Ohio State University., ▼c 2016.
260 1 ▼a Ann Arbor: ▼b ProQuest Dissertations & Theses, ▼c 2016.
300 ▼a 134 p.
500 ▼a Source: Dissertation Abstracts International, Volume: 79-10(E), Section: B.
500 ▼a Adviser: Abhay Satoskar.
5021 ▼a Thesis (Ph.D.)--The Ohio State University, 2016.
520 ▼a Proteins belonging to the TEC family of kinases are critical for the function of immune cells. One of the kinases in this family, BTK (Bruton's tyrosine kinase), is required for the function of B cells. BTK also plays key roles during the pathog
520 ▼a In addition to treating B cell malignancies, ibrutinib can potentially target other immune cells expressing BTK, such as dendritic cell (DCs). DCs, known as 'sentinels of the immune system', survey the body for the presence of 'danger signals' f
520 ▼a Since ibrutinib effectively inhibits the function of B cells, it could also be expanded for the treatment of infectious diseases involving B cells. B cells contribute to susceptibility to the parasitic, vector-borne disease cutaneous leishmanias
590 ▼a School code: 0168.
650 4 ▼a Microbiology.
650 4 ▼a Immunology.
690 ▼a 0410
690 ▼a 0982
71020 ▼a The Ohio State University. ▼b Microbiology.
7730 ▼t Dissertation Abstracts International ▼g 79-10B(E).
773 ▼t Dissertation Abstract International
790 ▼a 0168
791 ▼a Ph.D.
792 ▼a 2016
793 ▼a English
85640 ▼u http://www.riss.kr/pdu/ddodLink.do?id=T15000232 ▼n KERIS ▼z 이 자료의 원문은 한국교육학술정보원에서 제공합니다.
980 ▼a 201812 ▼f 2019
990 ▼a ***1012033